RCM-1 |
Catalog No.GC33117
One-Click Copy Product Info
|
RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 339163-65-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
RCM-1 is a FOXM1 inhibitor.
RCM-1 inhibits cellular proliferation via increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. Treatment with RCM-1 increases duration of mitosis and cell cycle in the cancer cell lines. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits migration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as growth of cancer cell colonies in vitro[1].
RCM-1 treatment reduces growth of Rd76-9 rhabdomyosarcomas in mice. RCM-1 treatment decreases tumor cell proliferation and increases apoptosis in Rd76-9 rhabdomyosarcoma tumors. The RCM-1-treated Rd76-9 tumors show reduced FOXM1 staining and decreased expression of proliferation-specific markers Ki67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase in apoptosis. RCM-1 treatment reduces growth of the B16-FlO melanoma tumors in mice. RCM-1 decreases the B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumor cell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces growth of the human H2122 lung adenocarcinoma in mice[1].
[1]. ARYL SULFONOHYDRAZIDES.WO2018057550A1.
Cell experiment: | Rd76-9 rhabdomyosarcoma, B16-FlO melanoma, H2122 lung adenocarcinoma, 4T1 breast carcinoma, MyC-CaP prostate carcinoma and KPC-2 pancreatic carcinoma cells are seeded in 6-well plates and incubated overnight. The cells are treated with 20 μM concentration of RCM-1 for 24, 48 and 72 h and cell growth is analyzed by counting alive cells using trypan blue. Cells treated with DMSO are used as controls[1]. |
Animal experiment: | Mice[1]Mouse Rd76-9 rhabdomyosarcoma cells (1×106 cells) are injected intramuscularly in the flanks of C56Bl/6J mice (n=8 mice per group). Seven days after the tumor cells inoculation, 40 μL of either Vehicle (DMSO) or RCM-1 (20 mg/kg body weight) are injected intraperitoneally in the animals every other day. The animals are sacrificed and tumors are harvested on day 16. RCM-1 treatment decreases Rd76-9 tumor growth as compared to the DMSO-treated group. Mouse B 16-FlO melanoma cells (1×106 cells) are injected subcutaneously in C56Bl/6J mice (n=7 animals per group). Three days after the tumor cell inoculation, 40 μL of either Vehicle (DMSO) or RCM1 (20 mg/Kg body weight) are injected intraperitoneally in the animals every other day. The animals are sacrificed and tumors are harvested on day 12[1]. |
References: [1]. ARYL SULFONOHYDRAZIDES.WO2018057550A1. | |
| Cas No. | 339163-65-4 | SDF | |
| Canonical SMILES | N#CC1=C(C2=CC=CS2)C=C(C3=CC=CS3)N=C1SCC(C4=CC=CS4)=O | ||
| Formula | C20H12N2OS4 | M.Wt | 424.58 |
| Solubility | DMSO : 16.67 mg/mL (39.26 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3553 mL | 11.7763 mL | 23.5527 mL |
| 5 mM | 471.1 μL | 2.3553 mL | 4.7105 mL |
| 10 mM | 235.5 μL | 1.1776 mL | 2.3553 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)